LARVOL is pleased to present a moderated discussion with top oncologists following AACR's Annual Meeting 2021. In the video below, Dr. Maureen Zakowski, Dr. Kim Chul, and Kinisha Gala discuss the practice-changing impact of AACR presentations in lung cancers.
On April 16, 2021 LARVOL hosted an oncology panel discussion on the top lung cancer clinical trial abstracts presented during the American Association for Cancer Research (AACR) Annual Meeting 2021, held on April 10-15, 2021. LARVOL's Kinisha Gala moderated the discussion between lung cancer KOLs Dr. Maureen Zakowski from Mount Sinai and Dr. Kim Chul from Georgetown University.
The discussion covered AACR abstract #CT003 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial, AACR abstract #CT039 Results from RATIONALE 303: A global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic NSCLC, and AACR abstract #CT041ORIENT-3: A randomized, open-label, phase 3 study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small-cell lung cancer (sqNSCLC).
This panel touched on the benefits and challenges of immunotherapy in both the localized and advanced setting in NSCLC.
Watch this video for the full discussion:
Our AACR Panel Series covered five therapeutic areas including lung cancer. Click below to read more about them and watch their video analysis.